Thromb Haemost 2019; 119(06): 1000-1020
DOI: 10.1055/s-0039-1683421
Atherosclerosis and Ischaemic Disease
Georg Thieme Verlag KG Stuttgart · New York

Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis

Anna Komosa
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Maciej Lesiak
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Zbigniew Krasiński
2   Department of General and Vascular Surgery, Poznan University of Medical Sciences, Poznan, Poland
,
Marek Grygier
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Andrzej Siniawski
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Włodzimierz Skorupski
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Anna Olasińska-Wiśniewska
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Małgorzata Pyda
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Aleksander Araszkiewicz
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Przemysław Mitkowski
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Stefan Grajek
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Tatiana Mularek-Kubzdela
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
,
Christian Hengstenberg
3   Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Jolanta M. Siller-Matula
1   1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
3   Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
› Author Affiliations
Funding None.
Further Information

Publication History

27 November 2018

25 January 2019

Publication Date:
27 March 2019 (online)

Abstract

Background and Aim The timing of P2Y12 inhibitor loading in patients undergoing percutaneous coronary intervention (PCI) is a matter of debate. The aim of our study was to compare the efficacy and safety of oral P2Y12 inhibitors: clopidogrel, ticagrelor and prasugrel administered at two different time points in relation to PCI: early (> 2 hours pre-PCI) versus late (< 2 hours pre-PCI or post-PCI).

Methods This is a systematic review and meta-analysis. Randomized controlled trials and non-randomized studies were included. Outcomes evaluated were combined major adverse cardiovascular events (MACEs), myocardial infarction (MI), target vessel revascularization, death and bleeding complications. Summary estimates of the relative risks with therapy were calculated.

Results Twenty-three studies met the selection criteria and included 60,907 patients. Early P2Y12 inhibitor loading was associated with a 22% relative risk reduction (RRR) of MACE (95% confidence interval [CI] = 0.68–0.89; p < 0.001). Early clopidogrel loading was associated with a 25% RRR of MACE (95% CI = 0.65–0.85; p < 0.001), a 30% RRR of MI (95% CI = 0.6–0.82; p < 0.0001) and 25% RRR of death (95% CI = 0.64–0.87; p = 0.0002), without an impact on major bleedings. In ST-elevation myocardial infarction as well as non-ST elevation acute coronary syndrome (NSTE-ACS), early clopidogrel loading resulted in 35 and 22% RRR in 30 days MACE (p < 0.001), respectively, with no impact in elective PCI. Whereas early loading with prasugrel and ticagrelor did not improve ischaemic outcomes, prasugrel administered early increased bleeding risks in NSTE-ACS.

Conclusion Early clopidogrel loading is associated with a better efficacy and similar safety, whereas timing of ticagrelor or prasugrel loading had no effects on ischaemic events.

 
  • References

  • 1 Siller-Matula J, Schrör K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97 (03) 385-393
  • 2 Valgimigli M, Bueno H, Byrne RA. , et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
  • 3 Montalescot G, Sideris G, Meuleman C. , et al; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48 (05) 931-938
  • 4 Siller-Matula JM, Haberl K, Prillinger K, Panzer S, Lang I, Jilma B. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res 2009; 123 (06) 874-880
  • 5 Jakubowski JA, Payne CD, Li YG. , et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99 (01) 215-222
  • 6 Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27 (09) 1038-1047
  • 7 Mehta SR, Tanguay JF, Eikelboom JW. , et al; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376 (9748): 1233-1243
  • 8 Szük T, Gyöngyösi M, Homorodi N. , et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 2007; 153 (02) 289-295
  • 9 Wallentin L, Becker RC, Budaj A. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
  • 10 Hochholzer W, Trenk D, Frundi D. , et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111 (20) 2560-2564
  • 11 Widimsky P, Motovská Z, Simek S. , et al; PRAGUE-8 Trial Investigators. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 2008; 29 (12) 1495-1503
  • 12 Steinhubl SR, Berger PB, Brennan DM, Topol EJ. ; CREDO Investigators. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47 (05) 939-943
  • 13 Zeymer U, Arntz HR, Darius H, Huber K, Senges J. Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design. Cardiology 2007; 108 (04) 265-272
  • 14 Montalescot G, Bolognese L, Dudek D. , et al; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369 (11) 999-1010
  • 15 Montalescot G, van 't Hof AW, Lapostolle F. , et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371 (11) 1016-1027
  • 16 Biondi-Zoccai GG, Lotrionte M, Abbate A. , et al. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ 2006; 332 (7535): 202-209
  • 17 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
  • 18 Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52 (19) 1557-1563
  • 19 Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157 (01) 148.e1-148.e5
  • 20 Payne CD, Li YG, Small DS. , et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007; 50 (05) 555-562
  • 21 Small DS, Farid NA, Payne CD. , et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48 (04) 475-484
  • 22 Jakubowski JA, Payne CD, Li YG. , et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99 (02) 409-415
  • 23 Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121 (04) 527-534
  • 24 Siller-Matula JM, Gouya G, Wolzt M, Jilma B. Cross validation of the multiple electrode aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009; 102 (02) 397-403
  • 25 Storey RF, Husted S, Harrington RA. , et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50 (19) 1852-1856
  • 26 Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. ; Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003; 145 (02) 239-247
  • 27 Serrano Jr CV, Ramires JA, Venturinelli M. , et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 1997; 29 (06) 1276-1283
  • 28 Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992; 12 (12) 1475-1487
  • 29 Saito Y, Wada H, Yamamuro M. , et al. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am J Hematol 1999; 61 (04) 238-242
  • 30 Mahemuti A, Meneveau N, Seronde MF. , et al. Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents. J Thromb Thrombolysis 2009; 28 (03) 333-341
  • 31 Vlaar PJ, Svilaas T, Damman K. , et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review. Circulation 2008; 118 (18) 1828-1836
  • 32 Steinhubl SR, Berger PB, Mann III JT. , et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19) 2411-2420
  • 33 Motovska Z, Widimsky P, Petr R. , et al. Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. Int J Cardiol 2010; 144 (02) 255-257
  • 34 Feldman DN, Fakorede F, Minutello RM, Bergman G, Moussa I, Wong SC. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2010; 105 (03) 323-332
  • 35 Davlouros PA, Arseniou A, Hahalis G. , et al. Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naive patients with stable or unstable angina: a comparison of two strategies. Am Heart J 2009; 158 (04) 585-591
  • 36 Mehta SR, Yusuf S, Peters RJ. , et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527-533
  • 37 Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol 2008; 51 (07) 701-707
  • 38 Zeymer U, Arntz HR, Darius H, Huber K, Senges J. Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design. Cardiology 2007; 108 (04) 265-272
  • 39 Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52 (21) 1693-1701
  • 40 Ebrahimi R, Dyke C, Mehran R. , et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2009; 53 (21) 1965-1972
  • 41 Anderson JL, Adams CD, Antman EM. , et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50 (07) e1-e157
  • 42 Rogers WJ, Canto JG, Barron HV, Boscarino JA, Shoultz DA, Every NR. ; Investigators in the National Registry of Myocardial Infarction. Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. J Am Coll Cardiol 2000; 35 (02) 371-379
  • 43 Siller-Matula JM, Akca B, Neunteufl T. , et al. Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets 2016; 27 (04) 373-377
  • 44 Siller-Matula JM, Hintermeier A, Kastner J. , et al. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. Vascul Pharmacol 2016; 79: 6-10
  • 45 Aalbers J. Prasugrel study addresses timing of thienopyridine loading dose in NSTEMI patients pre-PCI (the ACCOAST study). Cardiovasc J Afr 2011; 22 (03) 168
  • 46 Silvain J, Storey RF, Cayla G. , et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 2016; 116 (02) 369-378
  • 47 Montalescot G, Sechtem U, Achenbach S. , et al; Task Force Members; ESC Committee for Practice Guidelines; Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38) 2949-3003
  • 48 Lev EI, Kornowski R, Vaknin-Assa H. , et al. Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 2008; 101 (04) 435-439
  • 49 van der Heijden DJ, Westendorp IC, Riezebos RK. , et al. Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J Am Coll Cardiol 2004; 44 (01) 20-24
  • 50 Kandzari DE, Berger PB, Kastrati A. , et al; ISAR-REACT Study Investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44 (11) 2133-2136
  • 51 Zeymer U, Arntz HR, Mark B. , et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012; 101 (04) 305-312
  • 52 Almendro-Delia M, Gonzalez-Torres L, Garcia-Alcantara Á. , et al; ARIAM-Andalucía Group. Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively. Am J Cardiol 2015; 115 (08) 1019-1026
  • 53 Lincoff AM, Steinhubl SR, Manoukian SV. , et al; Acute Catheterization and Urgent Intervention Triage strategY of Trial Investigators. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. JACC Cardiovasc Interv 2008; 1 (06) 639-648
  • 54 Amin AP, Kennedy KF, Pencina M. , et al; EVENT Investigators. Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). Am J Cardiol 2011; 107 (12) 1751-1756
  • 55 Dörler J, Edlinger M, Alber HF. , et al; Austrian Acute PCI Investigators. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 2011; 32 (23) 2954-2961
  • 56 Fefer P, Hod H, Hammerman H. , et al. Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Am J Cardiol 2009; 104 (04) 514-518
  • 57 Chan AW, Moliterno DJ, Berger PB. , et al; TARGET Investigators. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 2003; 42 (07) 1188-1195
  • 58 Di Sciascio G, Patti G, Pasceri V, Gatto L, Colonna G, Montinaro A. ; ARMYDA-5 PRELOAD Investigators. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol 2010; 56 (07) 550-557
  • 59 Assali AR, Salloum J, Sdringola S. , et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol 2001; 88 (08) 884-886
  • 60 Sabatine MS, Cannon CP, Gibson CM. , et al; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294 (10) 1224-1232
  • 61 Wang TY, White JA, Tricoci P. , et al. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation 2011; 123 (07) 722-730